Icatibant peptide
Icatibant is a real peptide or peptide-based medicine with regulated uses. Approval, formulation and indication depend on jurisdiction and product.
Use this Icatibant peptide record to separate compound identity, human evidence, regulatory status and COA quality. These are related but distinct questions.
What is Icatibant?
Icatibant is a synthetic peptide antagonist of the bradykinin B2 receptor.
What does it do?
It blocks bradykinin-mediated vascular permeability and swelling.
Current use and status
Authorized use is limited to attacks of hereditary angioedema under product-specific labelling.
Approved prescription medicine for specific uses in at least one jurisdiction.
What the evidence does not prove
It treats a defined pathway and diagnosis; analytical identity alone cannot establish appropriate emergency use.
Certificate quality signals
- Certificate lot and label lot should agree
- Measured values should name their analytical method
- The issuing laboratory and report identifier should be independently traceable
Icatibant peptide reference records
Use the public chemistry and regulatory or clinical-study records to confirm identity and current product status. A database listing is not a product endorsement.
Learn how to assess peptide evidence
Read the peptide safety, sourcing and certificate-verification guides before interpreting a seller or laboratory claim.
Browse peptide guides